OBJECTIVE: Although studies have suggested that human cartilage (HC) gp-39 may be an antigen recognized by autoreactive CD4(+) T cells in rheumatoid arthritis, we previously failed to identify specific CD4(+) T cells in patients' synovial fluid or blood using a class II major histocompatibility complex-peptide tetramer composed of the immunodominant HC gp-39(263-275) epitope covalently linked to DR4. We undertook this study to better understand the parameters for specific binding of this tetramer. METHODS: DR4-transgenic mice were immunized with the HC gp-39 peptide, and a set of peptide-responsive hybridomas was derived. Hybridomas were stained with the DR4-gp-39 tetramer and cultured with increasing amounts of peptide in the presence of DR4-expressing antigen-presenting cells to determine functional avidity. RESULTS: Great variability was apparent in the ability of the tetramer to stain the hybridomas, and there was a strong correlation between the intensity of tetramer staining and functional avidity. Importantly, nearly 30% of the hybridomas did not stain with tetramer, and these cells exhibited relatively low functional avidity. Although the addition of an anti-T cell receptor (anti-TCR) monoclonal antibody during the staining procedure enhanced binding of the tetramer to a number of the hybridomas, a significant percentage remained unstainable. Analysis of TCR expression showed that >90% of the hybridomas expressed the same TCR beta-chain variable region (V(beta)10), and sequencing of the TCR junctional regions showed diversity in the third complementarity-determining region. CONCLUSION: These results suggest that immune responses dominated by relatively low-affinity TCR interactions, such as those that may occur in autoimmune disease, will be difficult to detect using standard tetramer techniques.
OBJECTIVE: Although studies have suggested that human cartilage (HC) gp-39 may be an antigen recognized by autoreactive CD4(+) T cells in rheumatoid arthritis, we previously failed to identify specific CD4(+) T cells in patients' synovial fluid or blood using a class II major histocompatibility complex-peptide tetramer composed of the immunodominant HC gp-39(263-275) epitope covalently linked to DR4. We undertook this study to better understand the parameters for specific binding of this tetramer. METHODS:DR4-transgenic mice were immunized with the HC gp-39 peptide, and a set of peptide-responsive hybridomas was derived. Hybridomas were stained with the DR4-gp-39 tetramer and cultured with increasing amounts of peptide in the presence of DR4-expressing antigen-presenting cells to determine functional avidity. RESULTS: Great variability was apparent in the ability of the tetramer to stain the hybridomas, and there was a strong correlation between the intensity of tetramer staining and functional avidity. Importantly, nearly 30% of the hybridomas did not stain with tetramer, and these cells exhibited relatively low functional avidity. Although the addition of an anti-T cell receptor (anti-TCR) monoclonal antibody during the staining procedure enhanced binding of the tetramer to a number of the hybridomas, a significant percentage remained unstainable. Analysis of TCR expression showed that >90% of the hybridomas expressed the same TCR beta-chain variable region (V(beta)10), and sequencing of the TCR junctional regions showed diversity in the third complementarity-determining region. CONCLUSION: These results suggest that immune responses dominated by relatively low-affinity TCR interactions, such as those that may occur in autoimmune disease, will be difficult to detect using standard tetramer techniques.
Authors: Natalie A Bowerman; Michael T Falta; Douglas G Mack; Fabian Wehrmann; Frances Crawford; Margaret M Mroz; Lisa A Maier; John W Kappler; Andrew P Fontenot Journal: J Immunol Date: 2014-04-09 Impact factor: 5.422
Authors: Li-Fen Lee; Robert Axtell; Guang Huan Tu; Kathryn Logronio; Jeanette Dilley; Jessica Yu; Mathias Rickert; Bora Han; Winston Evering; Michael G Walker; Jing Shi; Brigit A de Jong; Joep Killestein; Chris H Polman; Lawrence Steinman; John C Lin Journal: Sci Transl Med Date: 2011-07-27 Impact factor: 17.956
Authors: Laurent Malherbe; Linda Mark; Nicolas Fazilleau; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams Journal: Immunity Date: 2008-05-01 Impact factor: 31.745
Authors: James J Moon; H Hamlet Chu; Jason Hataye; Antonio J Pagán; Marion Pepper; James B McLachlan; Traci Zell; Marc K Jenkins Journal: Nat Protoc Date: 2009 Impact factor: 13.491
Authors: Ditza Levin; Richard J DiPaolo; Carine Brinster; Maria Jamela R Revilleza; Lisa F Boyd; Luc Teyton; Kannan Natarajan; Michael G Mage; Ethan M Shevach; David H Margulies Journal: Eur J Immunol Date: 2008-12 Impact factor: 5.532